newsfilter
← Latest News
Business Wire·

New England Journal of Medicine Publishes Results of the PULSAR Phase 2 Trial of Sotatercept in Patients with Pulmonary Arterial Hypertension

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that the New England Journal of Medicine has published results of the PULSAR Phase 2 trial of sotatercept in patients with pulmonary arterial hypertension (PAH).